|
1
|
Pasternak G, Hochhaus A, Schultheis B and
Hehlmann R: Chronic myelogenous leukemia: Molecular and cellular
aspects. J Cancer Res Clin Oncol. 124:643–660. 1998. View Article : Google Scholar
|
|
2
|
Lin X, Qureshi MZ, Attar R, Khalid S,
Tahir F, Yaqub A, Aslam A, Yaylim I, De Carlos Back LK, Farooqi AA,
et al: Targeting of BCR-ABL: Lessons learned from BCR-ABL
inhibition. Cell Mol Biol (Noisy-le-grand). 62:129–137. 2016.
|
|
3
|
Hochhaus A, Larson RA, Guilhot F, Radich
JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F,
Fujihara S, et al: IRIS Investigators: Long-term outcomes of
imatinib treatment for chronic myeloid leukemia. N Engl J Med.
376:917–927. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cortes JE, Kantarjian H, Shah NP, Bixby D,
Mauro MJ, Flinn I, O'Hare T, Hu S, Narasimhan NI, Rivera VM, et al:
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
N Engl J Med. 367:2075–2088. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cortes JE, Kim DW, Pinilla-Ibarz J, le
Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ,
Talpaz M, et al: PACE Investigators: A phase 2 trial of ponatinib
in Philadelphia chromosome-positive leukemias. N Engl J Med.
369:1783–1796. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hoy SM: Ponatinib: A review of its use in
adults with chronic myeloid leukaemia or Philadelphia
chromosome-positive acute lymphoblastic leukaemia. Drugs.
74:793–806. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moslehi JJ and Deininger M: Tyrosine
kinase inhibitor-associated cardiovascular toxicity in chronic
myeloid leukemia. J Clin Oncol. 33:4210–4218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mian AA, Rafiei A, Haberbosch I, Zeifman
A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill
B, et al: PF-114, a potent and selective inhibitor of native and
mutated BCR/ABL is active against Philadelphia chromosome-positive
(Ph+) leukemias harboring the T315I mutation. Leukemia.
29:1104–1114. 2015. View Article : Google Scholar
|
|
9
|
Chilov GG and Titov IY: Protein kinase
inhibitor (versions), use thereof for treating oncological diseases
and based pharmaceutical composition. Patent RU2477723 (C2). Filed
July 10, 2017; issued August 31, 2017.
|
|
10
|
Cellosaurus - a knowledge resource on cell
lines. Version 29. https://web.expasy.org/cellosaurus/CVCL_0002.
|
|
11
|
Liu D: The adaptor protein Crk in immune
response. Immunol Cell Biol. 92:80–89. 2014. View Article : Google Scholar :
|
|
12
|
Shchekotikhin AE, Dezhenkova LG, Tsvetkov
VB, Luzikov YN, Volodina YL, Tatarskiy VV Jr, Kalinina AA,
Treshalin MI, Treshalina HM, Romanenko VI, et al: Discovery of
antitumor anthra[2,3-b]furan-3-carboxamides: Optimization of
synthesis and evaluation of antitumor properties. Eur J Med Chem.
112:114–129. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahbar Saadat Y, Saeidi N, Zununi Vahed S,
Barzegari A and Barar J: An update to DNA ladder assay for
apoptosis detection. Bioimpacts. 5:25–28. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rossari F, Minutolo F and Orciuolo E:
Past, present, and future of Bcr-Abl inhibitors: From chemical
development to clinical efficacy. J Hematol Oncol. 11:842018.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haguet H, Douxfils J, Mullier F, Chatelain
C, Graux C and Dogné JM: Risk of arterial and venous occlusive
events in chronic myeloid leukemia patients treated with new
generation BCR-ABL tyrosine kinase inhibitors: A systematic review
and meta-analysis. Expert Opin Drug Saf. 16:5–12. 2017. View Article : Google Scholar
|
|
16
|
Wehrle J and von Bubnoff N: Ponatinib: A
third-generation inhibitor for the treatment of CML. Recent Results
Cancer Res. 212:109–118. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zulbaran-Rojas A, Lin HK, Shi Q, Williams
LA, George B, Garcia-Manero G, Jabbour E, O'Brien S, Ravandi F,
Wierda W, et al: A prospective analysis of symptom burden for
patients with chronic myeloid leukemia in chronic phase treated
with frontline second- and third-generation tyrosine kinase
inhibitors. Cancer Med. 7:5457–5469. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Aspinall-O'Dea M, Pierce A, Pellicano F,
Williamson AJ, Scott MT, Walker MJ, Holyoake TL and Whetton AD:
Antibody-based detection of protein phosphorylation status to track
the efficacy of novel therapies using nanogram protein quantities
from stem cells and cell lines. Nat Protoc. 10:149–168. 2015.
View Article : Google Scholar
|
|
19
|
Lux MP, Fasching PA, Schrauder MG, Hein A,
Jud SM, Rauh C and Beckmann MW: The PI3K pathway: Background and
treatment approaches. Breast Care (Basel). 11:398–404. 2016.
View Article : Google Scholar
|
|
20
|
Dey N, De P and Leyland-Jones B:
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell
signaling to clinical trials. Pharmacol Ther. 175:91–106. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nussinov R, Tsai CJ and Jang H: A new view
of pathway-driven drug resistance in tumor proliferation. Trends
Pharmacol Sci. 38:427–437. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Correia C, Lee SH, Meng XW, Vincelette ND,
Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging
understanding of Bcl-2 biology: Implications for neoplastic
progression and treatment. Biochim Biophys Acta. 1853:1658–1671.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schutters K and Reutelingsperger C:
Phosphatidylserine targeting for diagnosis and treatment of human
diseases. Apoptosis. 15:1072–1082. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chaitanya GV, Steven AJ and Babu PP:
PARP-1 cleavage fragments: Signatures of cell-death proteases in
neurodegeneration. Cell Commun Signal. 8:312010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bousoik E and Montazeri Aliabadi H: 'Do We
Know Jack' about JAK? A closer look at JAK/STAT signaling pathway.
Front Oncol. 8:2872018. View Article : Google Scholar
|
|
26
|
Ma L, Zhu Z, Jiang L, Sun X, Lu X, Zhou M,
Qian S and Jianyong L: Matrine suppresses cell growth of human
chronic myeloid leukemia cells via its inhibition of the
interleukin-6/Janus activated kinase/signal transducer and
activator of transcription 3 signaling cohort. Leuk Lymphoma.
56:2923–2930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma L, Xu Z, Wang J, Zhu Z, Lin G, Jiang L,
Lu X and Zou C: Matrine inhibits BCR/ABL mediated ERK/MAPK pathway
in human leukemia cells. Oncotarget. 8:108880–108889. 2017.
View Article : Google Scholar
|
|
28
|
Liu C, Nie D, Li J, Du X, Lu Y, Li Y, Zhou
J, Jin Y and Pan J: Antitumor effects of blocking protein
neddylation in T315I-BCR-ABL leukemia cells and leukemia stem
cells. Cancer Res. 78:1522–1536. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gu Y, Zheng W, Zhang J, Gan X, Ma X, Meng
Z, Chen T, Lu X, Wu Z, Huang W, et al: Aberrant activation of
CaMKIIγ accelerates chronic myeloid leukemia blast crisis.
Leukemia. 30:1282–1289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ and
Settleman J: Drug resistance via feedback activation of Stat3 in
oncogene-addicted cancer cells. Cancer Cell. 26:207–221. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mencalha AL, Corrêa S, Salles D, Du Rocher
B, Santiago MF and Abdelhay E: Inhibition of STAT3-interacting
protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation
and imatinib mesylate resistance in the chronic myeloid leukemia.
BMC Cancer. 14:8662014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H, Xie B, Kong Y, Tao Y, Yang G, Gao
M, Xu H, Zhan F, Shi J, Zhang Y, et al: Overexpression of RPS27a
contributes to enhanced chemoresistance of CML cells to imatinib by
the transactivated STAT3. Oncotarget. 7:18638–18650.
2016.PubMed/NCBI
|
|
33
|
Shi Y, Zhang Z, Qu X, Zhu X, Zhao L, Wei
R, Guo Q, Sun L, Yin X, Zhang Y, et al: Roles of STAT3 in leukemia
(Review). Int J Oncol. 53:7–20. 2018.PubMed/NCBI
|
|
34
|
Guanizo AC, Fernando CD, Garama DJ and
Gough DJ: STAT3: A multifaceted oncoprotein. Growth Factors.
36:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sgrignani J, Garofalo M, Matkovic M,
Merulla J, Catapano CV and Cavalli A: Structural biology of STAT3
and its implications for anticancer therapies development. Int J
Mol Sci. 19:E15912018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Al-Jamal HA, Jusoh SA, Yong AC, Asan JM,
Hassan R and Johan MF: Silencing of suppressor of cytokine
signaling-3 due to methylation results in phosphorylation of STAT3
in imatinib resistant BCR-ABL positive chronic myeloid leukemia
cells. Asian Pac J Cancer Prev. 15:4555–4561. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Eiring AM, Page BDG, Kraft IL, Mason CC,
Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar
AJ, et al: Combined STAT3 and BCR-ABL1 inhibition induces synthetic
lethality in therapy-resistant chronic myeloid leukemia. Leukemia.
31:1253–1254. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sweet K, Hazlehurst L, Sahakian E, Powers
J, Nodzon L, Kayali F, Hyland K, Nelson A and Pinilla-Ibarz J: A
phase I clinical trial of ruxolitinib in combination with nilotinib
in chronic myeloid leukemia patients with molecular evidence of
disease. Leuk Res. 74:89–96. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Singh H, Williams RT and Guy KR: Methods
and compositions for the treatment of Bcr-Abl positive
lymphoblastic leukemias. Patent US20150133462 A1. Filed May 23,
2013; issued May 14, 2015.
|
|
40
|
Sahu N, Chan E, Chu F, Pham T, Koeppen H,
Forrest W, Merchant M and Settleman J: Cotargeting of MEK and
PDGFR/STAT3 pathways to treat pancreatic ductal adenocarcinoma. Mol
Cancer Ther. 16:1729–1738. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ouédraogo ZG, Müller-Barthélémy M, Kemeny
JL, Dedieu V, Biau J, Khalil T, Raoelfils LI, Granzotto A, Pereira
B, Beaudoin C, et al: STAT3 serine 727 phosphorylation: A relevant
target to radiosen-sitize human glioblastoma. Brain Pathol.
26:18–30. 2016. View Article : Google Scholar
|
|
42
|
Zhou Q, Chen Y, Chen X, Zhao W, Zhong Y,
Wang R, Jin M, Qiu Y and Kong D: In vitro antileukemia activity of
ZSTK474 on K562 and multidrug resistant K562/A02 cells. Int J Biol
Sci. 12:631–638. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Haberbosch I, Rafiei A, Oancea C, Ottmann
GO, Ruthardt M and Mian AA: BCR: A new target in resistance
mediated by BCR/ABL-315I? Genes Cancer. 7:36–46. 2016.PubMed/NCBI
|
|
44
|
Mian AA, Schüll M, Zhao Z, Oancea C,
Hundertmark A, Beissert T, Ottmann OG and Ruthardt M: The
gatekeeper mutation T315I confers resistance against small
molecules by increasing or restoring the ABL-kinase activity
accompanied by aberrant transphosphorylation of endogenous BCR,
even in loss-of-function mutants of BCR/ABL. Leukemia.
23:1614–1621. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
NIH: U.S. National Library of Medicine.
ClinicalTrials. Study to evaluate tolerability, safety,
pharmacokinetics and preliminary efficacy of PF-114 for oral
administration in adults with Ph+ chronic myeloid leukemia, which
is resistant to the 2-nd generation Bcr-Abl inhibitors or Has T315I
mutation in the BCR-ABL gene. (NCT02885766). https://clinicaltrials.gov/ct2/show/NCT02885766.
|
